Kissel M, Peschke P, Subr V, Ulbrich K, Schuhmacher J, Debus J, Friedrich E
Department of Radiooncology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
PDA J Pharm Sci Technol. 2001 May-Jun;55(3):191-201.
To optimize polymer design for tumor directed drug delivery, the fate and the total body distribution of soluble synthetic macromolecules, derived from copolymers of [(N-2-(hydroxypropyl)methacrylamide] (HPMA) were monitored scintigraphically after radiolabeling with 131I during a seven day time window. Equimolar concentrations of radioiodinated copolymers of HPMA with small amounts of methacryloyltyrosinamide (pHPMA) differing in molecular weight (23.4 kD, 27.3 kD, 30.5 kD, 44 kD, 58.4 kD, 60.1 kD) were injected intravenously into Copenhagen rats bearing Dunning prostate carcinomas (subline R3327-AT1). Scintigraphic data were validated by determining absolute amounts of [131I]pHPMA in both tumor tissue and normal organs after sacrificing the animals. Copolymers were cleared from blood circulation in a molecular-weight dependent manner, either via excretion or by extravasation into normal and neoplastic tissues. While distribution patterns for pHPMAs in normal organs were quite similar, absolute amounts of copolymer uptake differed. The higher the molecular weight, the more radioactivity was taken up by the organs. Highest amounts of radioactivity were seen in the lung, liver, and spleen. In solid tumors, kinetics of pHPMA accumulation was clearly dependent on molecular weight. pHPMAs below the renal threshold peaked at 24 hours p.i. and then remained constant. In contrast, copolymers above the renal clearance threshold displayed a continuous accumulation reaching a significantly higher tumor uptake, presumably due to the very small or non existent polymer release from tumor tissue. Absolute amounts of tumor uptake determined by dissection analysis were 0.5 +/- 0.1% of injected dose/g tissue for the 27.3 kD pHPMA and 1.2 +/- 0.1% for the 60.1 kD pHPMA, respectively. In conclusion, our results demonstrate the influence of the molecular weight of the synthetic polymer pHPMA on plasma circulation time, excretion and organ clearance. While pHPMAs are cleared from all normal tissues except the spleen quite effectively, these polymers accumulate in solid tumors in a size dependent manner, due to the well known "enhanced permeability and retention" (EPR) effect. These data are of fundamental interest for ongoing studies on the pharmacokinetics of synthetic polymers, especially when these molecules are conjugated with targeting moieties and therapeutic or diagnostic agents.
为优化用于肿瘤靶向给药的聚合物设计,在用¹³¹I进行放射性标记后,通过闪烁扫描法在7天的时间窗口内监测了由(N - 2 - (羟丙基)甲基丙烯酰胺共聚物衍生的可溶性合成大分子的命运和全身分布情况。将等摩尔浓度的不同分子量(23.4 kD、27.3 kD、30.5 kD、44 kD、58.4 kD、60.1 kD)的含少量甲基丙烯酰酪氨酸酰胺的HPMA放射性碘化共聚物(pHPMA)静脉注射到患有邓宁前列腺癌(亚系R3327 - AT1)的哥本哈根大鼠体内。在处死动物后,通过测定肿瘤组织和正常器官中[¹³¹I]pHPMA的绝对量来验证闪烁扫描数据。共聚物以分子量依赖的方式从血液循环中清除,要么通过排泄,要么通过外渗进入正常组织和肿瘤组织。虽然pHPMA在正常器官中的分布模式相当相似,但共聚物摄取的绝对量有所不同。分子量越高,器官摄取的放射性就越多。在肺、肝和脾中观察到的放射性量最高。在实体瘤中,pHPMA积累的动力学明显依赖于分子量。低于肾阈值的pHPMA在注射后24小时达到峰值,然后保持恒定。相比之下,高于肾清除阈值的共聚物显示出持续积累,肿瘤摄取量显著更高,这可能是由于肿瘤组织中聚合物释放非常少或不存在。通过解剖分析确定的肿瘤摄取绝对量,对于27.3 kD的pHPMA为注射剂量/克组织的0.5±0.1%,对于60.1 kD的pHPMA为1.2±0.1%。总之,我们的结果证明了合成聚合物pHPMA的分子量对血浆循环时间、排泄和器官清除的影响。虽然pHPMA能相当有效地从除脾脏外的所有正常组织中清除,但由于众所周知的“增强渗透和滞留”(EPR)效应,这些聚合物以大小依赖的方式在实体瘤中积累。这些数据对于正在进行的合成聚合物药代动力学研究具有重要的基础意义,尤其是当这些分子与靶向部分以及治疗或诊断剂偶联时。